Put companies on watchlist
MediClin AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MediClin AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1624717
04 May 2023 12:51PM

MediClin AG: Encouraging development of Group sales in the first quarter of 2023


EQS-News: MediClin AG / Key word(s): Quarter Results
MediClin AG: Encouraging development of Group sales in the first quarter of 2023

04.05.2023 / 12:51 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, May 4, 2022

Encouraging development of Group sales in the first quarter of 2023

 In the first three months of 2023, MEDICLIN generated Group sales of EUR 176.7 mill. Sales in the first quarter of 2022 in the amount of EUR 174.2 mill. had still included EUR 7.7 mill. in benefits under the Corona protective shield. These benefits are no longer paid since the end of the previous year. In operating terms, therefore, sales improved by EUR 9.8 mill. or 5.9 % in the first quarter of the current financial year. The Group-EBIT improved by EUR 1.0 mill. to EUR –1.7 mill. despite the higher burdens.

On the costs side, the cost of raw materials and consumables used was EUR 36.4 mill., corresponding to an increase of EUR 2.6 mill. or 7.6 % compared to the prior-year value. These cost increases were caused by higher energy costs and higher expenses for external medical staff. Staff costs climbed by EUR 4.5 mill. or 4.0 %, respectively.

Gross capital expenditure amounted to EUR 8.1 mill. in the first quarter of 2023 (Q1 2022: EUR 3.8 mill.). Cash and cash equivalents as of 31 March 2023 amounted to EUR 89.8 mill. (31.12.2022: EUR 88.0 mill.).

MEDICLIN intends to build on its strengths

MEDICLIN’s strong points are rehabilitation and interdisciplinary cooperation between acute care and rehabilitation. With regard to the rehabilitation or post-acute sector, however, the Company expects rising demand for preventive care and more extensive therapeutic post-acute care. MEDICLIN intends to actively contribute to shaping this trend with outpatient and digital solutions.

Mercurius Health acquires Robert Janker Klinik in Bonn

The Robert Janker Klinik is specialised in radiotherapy, interventional radiology and palliative care. MEDICLIN has found the right partner in Mercurius Health for the further development of the clinic, which specialises in minimally invasive diagnostics and cutting-edge oncology therapies. The Medical Care Center Bonn, which belongs to the clinic, will also be transferred. The transaction was signed on January 11, 2023, and has been completed following regulatory approvals at the current time.

Outlook

The Management Board assumes that, driven by rising demand for medical, therapeutic and nursing care services, sales and earnings will increase in 2023 − subject to material adverse changes in the economic or regulatory environment.

The interim report as of 31 March 2023 is available from today under www.mediclin.de in German and English.

 

About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)

MEDICLIN includes 33 clinics, six care facilities and eleven medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

 

MEDICLIN ─ a company of the Asklepios Group



04.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1624717

 
End of News EQS News Service

1624717  04.05.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1624717&application_name=news&site_id=boersengefluester_html
Visual performance / price development - MediClin AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.